Vaccination with heat shock protein-peptide complexes: From basic science to clinical applications

Expert Review of Vaccines

Volumn 2, Issue 3, 2003, Pages 369-379

  Hoos, Axel ^a   Levey, Daniel L ^a  

^a Antigenics Inc   (United States)

Author keywords

Aurologous cancer vaccine; Heat shock protiens; Immunotherapy; Translational medicine

Indexed keywords

AG 702; CANCER VACCINE; HEAT SHOCK PROTEIN E7; HEAT SHOCK PROTEIN PEPTIDE COMPLEX 70; HEAT SHOCK PROTEIN PEPTIDE COMPLEX 96; IMATINIB; ONCOPHAGE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

CANCER SURVIVAL; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION; INJECTION PAIN; KIDNEY CARCINOMA; LYMPHOMA; MELANOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; AUTOANTIGENS; CANCER VACCINES; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; DIGESTIVE SYSTEM NEOPLASMS; HEAT-SHOCK PROTEINS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, NATURAL; IMMUNOTHERAPY, ACTIVE; KIDNEY NEOPLASMS; MICE; MOLECULAR CHAPERONES; NEOPLASMS; ORGAN SPECIFICITY; T-LYMPHOCYTE SUBSETS; VACCINATION; VACCINES, SUBUNIT;

EID: 0037833596     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.3.369     Document Type: Review

References (76)

1. Srivastava PK, Das MR. Serologically unique surface antigen of a rat hepatoma is also its tumor-associated transplantation antigen. Int. J. Cancer 33 (3), 417-422 (1984).
2. Srivastava PK, DeLeo AB, Old LJ. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl Acad. Sci. USA 83(10), 3407-3411 (1986).
3. Ullrich SJ, Robinson EA, Law LW, Willingham M, Appella E. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc. Natl Acad. Sci. USA 83(10), 3121-3125 (1986).
4. Schild H, Rammensee HG. gp96 - the immune system's Swiss army knife. Nat. Immunol. 1(2), 100-101 (2000).
5. Oettgen HF, Old LJ. The history of cancer immunotherapy. In: Biologic Therapy of Cancer. Devita VT, Hellman S, Rosenberg SA (Eds). JB Lippincott, London, UK, 87-119 (1991).
6. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3, 323-326 (1943).
7. Old LJ, Boyse EA, Clarke DA, Carswell EA Antigenic properties of chemically induced tumors. Ann. NY Acad. Sci. 101, 80-106 (1962).
8. Prehn R, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769-778 (1957).
9. Klein G, Sjorgen HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572 (1960).
10. Srivastava PK. Do human cancers express shared protective antigens? Or the necessity of remembrance of things past. Semin. Immunol. 8(5), 295-302 (1997).
11. Srivastava PK. Immunotherapy of human cancer: lessons from mice. Nat. Immunol. 1(5), 363-366 (2000).
12. Srivastava PK, Chen YT, Old LJ. 5′-structural analysis of genes encoding polymorphic antigens of chemically induced tumors. Proc. Natl Acad. Sci. USA 84(11), 3807-3811 (1987).
13. Srivastava PK, Maki RG. Stress-induced proteins in immune response to cancer. Curr. Top. Microbiol. Immunol. 167, 109-123 (1991).
14. Srivastava PK. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Ann. Rev. Immunol. 20, 395-425 (2002).
15. Zhu X, Zhao X, Burkholder WF et al. Structural analysis of substrate binding by the molecular chaperone DnaK. Science 272(5268), 1606-1614 (1996).
16. Srivastava PK. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2, 185-194 (2002).
17. + T cells in vivo. Proc. Natl Acad. Sci. USA 91(8), 3077-3081 (1994).
18. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39(2), 93-98 (1994).
19. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1(2), 151-155 (2000).
20. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14(3), 303-313 (2001).
21. Habich C, Baumgart K, Kolb H, Burkart V. The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins J. Immunol. 168, 569-576 (2002).
22. Hilf N, Sing-Jasuja H, Schwarzmaier P, Gouttefangeas C, Rammensee HG, Schild H. Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood 99, 3676-3682 (2002).
23. Skokos D, Botros HG, Demeure C et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J. Immunol. 170 (6), 3037-3045 (2003).
24. Berwin B, Hart JP, Pizzo SV, Nicchitta CV. Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides. J. Immunol. 168(9), 4282-4286 (2002).
25. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269(5230), 1585-1588 (1995).
26. Blachere NE, Udono H, Janetzki S, Li Z, Heike M, Srivastava PK. Heat shock protein vaccines against cancer. J. Immunother. 14(4), 352-356 (1993).
27. Blachere NE, Li Z, Chandawarkar RY et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186(8), 1315-1322 (1997). This study definitively demonstrated the adjuvant activity of mammalian HSPs. CTL response was shown to be induced to multiple antigens complexed to HSPs.
28. Manjili MH, Henderson R, Wang XY et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res. 62(6), 1737-1742 (2002).
29. Suzue K, Young RA. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 156(2), 873-879 (1996).
30. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) Type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121(2), 216-225 (2000).
31. + CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Vaccine 17(4), 373-383 (1999).
32. Udono H, Yamano T, Kawabata Y, Ueda M, Yui K. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int. Immunol. 13(10), 1233-1242 (2001).
33. Anthony LS, Liu H, Rowse G et al. Induction of HBcAg-specific CTL responses by a heat shock protein fused to the core antigen of the Hepatitis B virus. Proceedings of the 5th Annual Conference on Vaccine Research, Baltimore, MD, USA (2002).
34. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol. 12(11), 1539-1546 (2000).
35. Singh-Jasuja H, Scherer HU, Hilf N et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 30(18), 2211-2215 (2000).
36. Lehner T, Bergmeier LA, Wang Y et al. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur. J. Immunol. 30(2), 594-603 (2000).
37. Panjwani NN, Popova L, Srivastava PK. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. J. Immunol. 168(6), 2997-3003 (2002).
38. Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J. Immunol. 162(6), 3212-3219 (1999).
39. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278(5335), 117-120 (1997).
40. + cells in vivo. J. Immunol. 165(11), 6029-6035 (2000). This study demonstrated the ability of intradermally injected HSPs to mobilize and mature DCs in vivo as shown visually and in functional assays.
41. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152, 5398-5403 (1994).
42. Ciupitu AM, Petersson M, Kono K, Charo J, Kiessling R. Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses. Cancer Immunol. Immunother. 51, 163-170 (2002).
43. Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchitta CV. GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J. Exp. Med. 196(11), 1447-1459 (2002).
44. Janetzki S, Polla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96: A pilot study. Int. J. Cancer 88(2), 232-238, (2000).
45. Castelli C, Ciupitu AM, Rini F et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61(1), 222-227 (2001). This study is the first demonstration in a human system that HSP-peptide complexes purified from tumor cells can activate CTL clones specific for defined tumor antigens.
46. Noessner E, Gastpar R, Milani V et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J. Immunol. 169(10), 5424-5432 (2002).
47. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89(12), 2646-2654 (2000).
48. Michils A, Dutry D, de Beyl VZ, Remmelink M, de Maertelaer V, Rocmans P. Peripheral blood mononuclear cell proliferation to heat shock protein-70 derived from autologous lung carcinoma. Am. J. Respir. Crit. Care Med. 166(5), 749-753 (2002).
49. Meng SD, Gao T, Gao GF, Tien P. HBV-specific peptide associated with heat-shock protein gp96. Lancet 357(9255), 528-529 (2001).
50. Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20, 4169-4180 (2002). This publication marked one of the first demonstrations of complete dinical response in metastatic melanoma patients using a monotherapy with minimal toxicities.
51. Mazzaferro V, Coppa J, Carraba MG et al. Vaccination with autologous tumor derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. (2003) (In press).
52. Asea A, Kraeft SK, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6(4), 435-442 (2000).
53. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for hsp60 activation of mononuclear cells. J. Immunol. 164(1), 13-17 (2000).
54. Somersan S, Larsson M, Fontenau JF, Basu S, Srivastava P, Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J. Immunol. 167(9), 4544-4852 (2001).
55. Cohen L, de Moor C, Parker PA, Amato, RJ. Quality of life in patients with metastatic renal cell carcinoma participating in a Phase I trial of an autologous tumor-derived vaccine. Urol. Oncol. 7, 119-124 (2002).
56. Amato RJ, Wood LS, Savary C et al. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein-peptide complex-96 (HSPPC-96) with or without interleukin-2. Proceedings of the American Society of Clinical Oncology., New Orleans, LA, USA, 1782 (2000).
57. Amato RJ, Murray L, Wood L, Savary C, Tomasovic S, Reitsma D. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein-peptide complex-96 (HSPPC-96) vaccine. Proceedings of the American Society of Clinical Oncology, Atlanta, GA, USA, 1278 (1999).
58. Eton O, East M, Ross MI et al. Autologous tumor-derived heat shock protein-peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Proceedings of the American Association for Cancer Research, San Francisco, CA, USA, 3463 (2000).
59. Heike M, Hertkorn C, Reitsma DJ et al. Pilot trial of vaccination with autologous tumor-derived gp96 heat shock proteinpeptide complex (HSPPC-96) in patients after surgery for gastric carcinoma. Proceedings of the American Society of Clinical Oncology, New Orleans, LA, USA, 1825 (2000).
60. Lewis JJ, Janetzki S, Livingston PO. Pilot trial of vaccination with autologous tumor derived gp96 heat shock protein-peptide complex-96 (HSPPC-96) in patients with resected pancreatic adenocarcinoma. Proceedings of the American Society of Clinical Oncology, Atlanta, GA, USA, 1687 (1999).
61. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR, Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum 45(4), 502-507 (2002).
62. Wang XY, Kazim L, Repasky EA, Subjeck JR. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166(1), 490-497 (2001).
63. Kovalchin JT, Murthy AS, Horattas MC, Guyton DP Chandawarkar RY. Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96 Cancer Immun. 1, 7-15 (2001).
64. Palladino MA, Srivastava PK, Oettgen HF, DeLeo AB. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. I. Detection by a cloned cytotoxic T cell line. Cancer Res. 47(19), 5074-5079 (1987).
65. Janetzki S, Blachere NF, Srivastava PK. Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96. J. Immunother. 21(4), 269-276 (1998).
66. Nicchitta CV. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr. Opin. Immunol. 10(1), 103-109 (1998).
67. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol. Immunother. 49(9), 476-484 (2000).
68. Sato K, Torimoto Y, Tamura Y et al. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood 98 (6), 1852-1857 (2001).
69. Robert J, Menoret A, Basu S, Cohen N, Srivastava PK. Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70. Eur. J. Immunol. 31(1), 186-195 (2001). This study provides a convincing example, in a model of tumor immunity in Xenopus, of the conservation of immunological functions of HSPs through evolution.
70. Yedavelli SPK, Guo L, Daou ME, Srivastava PK. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int. J. Mol. Med. 4(3), 243-248 (1999).
71. Blachere NE. The role of heat shock proteins in antigen presentation by MHC class I molecules. Doctoral dissertation, Fordham University, Bronx, NY, USA (1998).
72. Heikema A, Agsteribbe E, Wiscjut J, Huckriede A. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol. Lett. 57(1-3), 69-74 (1997).
73. Kumaraguru U, Gierynska M, Norman S, Bruce BD, Rouse BT. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J. Virol. 76(1), 136-141 (2002).
74. Ciupitu AM, Petersson M, O'Donnell CL, et al. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187(5), 685-691 (1998). This study is the first demonstration that HSP-peptide complexes provide protective immunity to challenge with live virus in a murine model.
75. Navaratnam M, Deshpande MS, Hariharan MJ, Zatechka DS, Srikumaran S. Heat shock protein-peptide complexes elicit cytotoxic T-lymphocyte and antibody responses specific for bovine herpesvirus 1. Vaccine 19(11-12), 1425-1434 (2001).
76. Zugel U, Sponaas AM, Neckermann J, Schoel B, Kaufmann SH. gp96-peptide vaccination of mice against intracellular bacteria. Infect. Immunol. 69(6), 4164-4167 (2001).